PAREXEL International and Proteome Sciences have formed an alliance focused on enhancing PAREXEL’s biomarker capabilities for early phase clinical development. PAREXEL will use Proteome Sciences’ PS Biomarker Services protein and peptide biomarker capabilities to support earlier assessments of new compounds in development through biomarker discovery and qualification within clinical trials The alliance allows PAREXEL to offer mass spectrometric and pharmacokinetic assays for protein and peptide compounds.

“Biomarker analyses are anticipated to become increasingly important in clinical trials to understand the biological activity and safety profile of candidate therapies. Our early phase experts are focused on helping customers make better decisions faster about their compounds in development,” said Michelle Middle, MB ChB, corporate vice president and worldwide head of Early Phase, PAREXEL International. “Our alliance with Proteome Sciences reinforces our commitment to provide customers with significant expertise to help them select relevant biomarkers for their development programs, interpret results, and determine implications for their therapies.”

Christopher Pearce, chief executive officer of Proteome Sciences, said, “We are very pleased to have PS Biomarker Services selected by PAREXEL as a preferred provider of protein and peptide biomarker services. We believe that the current regulatory requirements for biomarkers in drug development and diagnostics coupled with the need for fast, flexible and cost effective workflows have meant that specialist services will be increasingly required.”